Literature DB >> 28903492

Editor's Highlight: Nlrp3 Is Required for Inflammatory Changes and Nigral Cell Loss Resulting From Chronic Intragastric Rotenone Exposure in Mice.

Eileen M Martinez1, Alison L Young1, Yash R Patankar2, Brent L Berwin2, Li Wang3, Katharine M von Herrmann1, Jaclyn M Weier1, Matthew C Havrda1.   

Abstract

Complex interactions between genetic and environmental factors are widely believed to underlie the incidence and progression of Parkinson's disease (PD). Rotenone is a naturally occurring metabolic toxin employed as an insecticide and piscicide identified as a risk factor for the development of PD in agricultural workers. The Nlrp3 inflammasome is an intracellular mediator that can initiate an inflammatory cascade in response to cellular stress. Reports by others indicating that NLRP3 expression was detectable in tissues obtained from Alzheimer's disease patients and that the PD-associated protein α-synuclein could activate inflammasomes in cultured glial cells, prompted us to test the prediction that Nlrp3 was required for the development of Parkinson's-like changes resulting from rotenone exposure in mice. We exposed wild type and Nlrp3-/- mice to chronic low doses of intragastric rotenone and conducted longitudinal behavioral and serum cytokine analysis followed by evaluation of neuroinflammatory and neurodegenerative endpoints in brain tissues. We observed progressive rotenone-dependent changes in serum cytokine levels and circulating leukocytes in wild type mice not observed in Nlrp3-/- mice. Analysis of brain tissues revealed Nlrp3-dependent neuroinflammation and nigral cell loss in mice exposed to rotenone as compared with mice exposed to vehicle alone. Together, our findings provide compelling evidence of a role for Nlrp3 in nigral degeneration and neuroinflammation resulting from systemic rotenone exposure and suggest that the suppression of NLRP3 activity may be a rational neuroprotective strategy for toxin-associated PD.
© The Author 2017. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Nlrp3; Parkinson’s; inflammasome; neuroinflammation; rotenone

Mesh:

Substances:

Year:  2017        PMID: 28903492      PMCID: PMC5837210          DOI: 10.1093/toxsci/kfx117

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  59 in total

Review 1.  Genetics of Parkinson's disease.

Authors:  Christine Klein; Ana Westenberger
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

2.  NLRP3 inflammasome activation mediates estrogen deficiency-induced depression- and anxiety-like behavior and hippocampal inflammation in mice.

Authors:  Yongjun Xu; Hui Sheng; Qingyue Bao; Yujun Wang; Jianqiang Lu; Xin Ni
Journal:  Brain Behav Immun       Date:  2016-02-27       Impact factor: 7.217

3.  A role for mitochondria in NLRP3 inflammasome activation.

Authors:  Rongbin Zhou; Amir S Yazdi; Philippe Menu; Jürg Tschopp
Journal:  Nature       Date:  2010-12-01       Impact factor: 49.962

4.  Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice.

Authors:  Masatoshi Inden; Yoshihisa Kitamura; Mari Abe; Aya Tamaki; Kazuyuki Takata; Takashi Taniguchi
Journal:  Biol Pharm Bull       Date:  2011       Impact factor: 2.233

Review 5.  Lessons from the rotenone model of Parkinson's disease.

Authors:  J Timothy Greenamyre; Jason R Cannon; Robert Drolet; Pier-Giorgio Mastroberardino
Journal:  Trends Pharmacol Sci       Date:  2010-01-22       Impact factor: 14.819

6.  Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration.

Authors:  Solomon S Shaftel; Thaddeus J Carlson; John A Olschowka; Stephanos Kyrkanides; Sarah B Matousek; M Kerry O'Banion
Journal:  J Neurosci       Date:  2007-08-29       Impact factor: 6.167

7.  Caspase-1 Deficiency Alleviates Dopaminergic Neuronal Death via Inhibiting Caspase-7/AIF Pathway in MPTP/p Mouse Model of Parkinson's Disease.

Authors:  Chen Qiao; Lin-Xia Zhang; Xi-Yang Sun; Jian-Hua Ding; Ming Lu; Gang Hu
Journal:  Mol Neurobiol       Date:  2016-06-23       Impact factor: 5.590

8.  Gene-gene and gene-environment interaction on the risk of Parkinson's disease.

Authors:  Neeraj Kumar Singh; Basu Dev Banerjee; Kiran Bala; Mitrabasu Chhillar; Neelam Chhillar
Journal:  Curr Aging Sci       Date:  2014

9.  NLRP3 Inflammasome Is Expressed and Functional in Mouse Brain Microglia but Not in Astrocytes.

Authors:  Audrey Gustin; Mélanie Kirchmeyer; Eric Koncina; Paul Felten; Sophie Losciuto; Tony Heurtaux; Aubry Tardivel; Paul Heuschling; Catherine Dostert
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

10.  Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice.

Authors:  Francisco Pan-Montojo; Oleg Anichtchik; Yanina Dening; Lilla Knels; Stefan Pursche; Roland Jung; Sandra Jackson; Gabriele Gille; Maria Grazia Spillantini; Heinz Reichmann; Richard H W Funk
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

View more
  16 in total

Review 1.  Inflammasome Activation in Parkinson's Disease.

Authors:  Shannon Jewell; Ashane M Herath; Richard Gordon
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

2.  Astrocyte inflammatory signaling mediates α-synuclein aggregation and dopaminergic neuronal loss following viral encephalitis.

Authors:  Collin M Bantle; Savannah M Rocha; C Tenley French; Aaron T Phillips; Kevin Tran; Kenneth E Olson; Todd A Bass; Tawfik Aboellail; Richard J Smeyne; Ronald B Tjalkens
Journal:  Exp Neurol       Date:  2021-08-26       Impact factor: 5.620

Review 3.  Mechanism of Gene-Environment Interactions Driving Glial Activation in Parkinson's Diseases.

Authors:  Souvarish Sarkar
Journal:  Curr Environ Health Rep       Date:  2021-05-27

Review 4.  Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy.

Authors:  Fillipe M de Araújo; Lorena Cuenca-Bermejo; Emiliano Fernández-Villalba; Silvia L Costa; Victor Diogenes A Silva; Maria Trinidad Herrero
Journal:  Cell Mol Neurobiol       Date:  2021-01-02       Impact factor: 5.046

5.  Slc6a3-dependent expression of a CAPS-associated Nlrp3 allele results in progressive behavioral abnormalities and neuroinflammation in aging mice.

Authors:  Katharine M von Herrmann; Faith L Anderson; Eileen M Martinez; Alison L Young; Matthew C Havrda
Journal:  J Neuroinflammation       Date:  2020-07-17       Impact factor: 8.322

6.  NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson's disease.

Authors:  Katharine M von Herrmann; Lucas A Salas; Eileen M Martinez; Alison L Young; Joseph M Howard; Mary S Feldman; Brock C Christensen; Owen M Wilkins; Stephen L Lee; William F Hickey; Matthew C Havrda
Journal:  NPJ Parkinsons Dis       Date:  2018-08-15

Review 7.  Mechanistic Studies of Idiosyncratic DILI: Clinical Implications.

Authors:  Jack Uetrecht
Journal:  Front Pharmacol       Date:  2019-07-26       Impact factor: 5.810

8.  α-Synuclein evokes NLRP3 inflammasome-mediated IL-1β secretion from primary human microglia.

Authors:  Adrianne F Pike; Tatiana Varanita; Maaike A C Herrebout; Bonnie C Plug; Jeroen Kole; René J P Musters; Charlotte E Teunissen; Jeroen J M Hoozemans; Luigi Bubacco; Robert Veerhuis
Journal:  Glia       Date:  2021-01-28       Impact factor: 7.452

9.  miRNAs and target genes in the blood as biomarkers for the early diagnosis of Parkinson's disease.

Authors:  Xiaoting Liu; Jinhu Chen; Tianyuan Guan; Hui Yao; Wenpei Zhang; Zhenlong Guan; Yanqin Wang
Journal:  BMC Syst Biol       Date:  2019-01-21

10.  Pharmacological Inhibition of HDAC6 Attenuates NLRP3 Inflammatory Response and Protects Dopaminergic Neurons in Experimental Models of Parkinson's Disease.

Authors:  Shaoqi Yan; Xinbing Wei; Wencheng Jian; Yue Qin; Jia Liu; Shaowei Zhu; Fan Jiang; Haiyan Lou; Bin Zhang
Journal:  Front Aging Neurosci       Date:  2020-03-31       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.